Alan D. Sobel - 08 Aug 2025 Form 4 Insider Report for Cytosorbents Corp (CTSO)

Reporting relationship: Director
Issuer ticker: CTSO
Reported as of: 08 Aug 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 08 Aug 2025, 19:33:14 UTC
Prior SEC filing: 26 Feb 2025
Source filing: View source filing
Reporting owner signature: /s/ Peter J. Mariani attorney-in-fact Alan D. Sobel

Key filing fact

Alan D. Sobel filed Form 4 for Cytosorbents Corp (CTSO) on 08 Aug 2025.

Key facts

This page summarizes Alan D. Sobel's Form 4 filing for Cytosorbents Corp (CTSO).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 08 Aug 2025, 19:33.

Change

Previous filing in this sequence was filed on 26 Feb 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001639386 Primary reporting owner

Sobel Alan D.

Relationship: Director
Address: C/O CYTOSORBENTS CORPORATION, 305 COLLEGE ROAD EAST, PRINCETON
Signature: /s/ Peter J. Mariani attorney-in-fact Alan D. Sobel
Signature date: 08 Aug 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CTSO holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 145,757
Date: 08 Aug 2025
Ownership: Direct
Footnotes: F1

CTSO holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 2,000
Date: 08 Aug 2025
Ownership: Bernard Sobel Revocable Trust
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CTSO transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +22,000
Change %
Price: $0.000000
Shares after: 22,000
Date: 08 Aug 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 22,000
Exercise price: $1.00
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Includes (i) the following restricted stock units ("RSUs") that will be settled into Common Stock upon vesting upon a "Change in Control" of the Company, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 3,300 RSUs granted on March 15, 2018, (b) 6,000 RSUs granted on February 24, 2017, (c) 5,000 RSUs granted on June 7, 2016, and (d) 55,000 RSUs granted on April 8, 2015 and (ii) 76,457 shares of Common Stock owned directly by the Reporting Person.

Footnote F2

These shares are held in the Bernard Sobel Revocable Trust (the "Trust"), for which the Reporting Person is a trustee and a named beneficiary. Accordingly, the Reporting Person may be deemed the beneficial owner of the shares held in the Trust.

Footnote F3

The stock options were granted pursuant to the Plan. The shares underlying the stock options will vest in four (4) equal quarterly installments over a period of one year following the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

SEC remarks

Exhibit 24.1 Power of Attorney